or Try an Advanced Search...

    Technical Analysis for MBRX - Moleculin Biotech, Inc.

    Grade Last Price % Change Price Change
    F 5.03 -0.99% -0.05
    MBRX closed up 0.99 percent on Friday, May 17, 2024, on 18 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical MBRX trend table...
    Date Alert Name Type % Chg
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.99%
    NR7 Range Contraction -0.99%
    Narrow Range Bar Range Contraction -0.99%
    Inside Day Range Contraction -0.99%
    Up 3 Days in a Row Strength -0.99%
    Up 4 Days in a Row Strength -0.99%
    Up 3 Days in a Row Strength 0.00%
    NR7 Range Contraction 2.23%
    Gapped Up Strength 2.23%
    Crossed Above 20 DMA Bullish 3.71%
    Older End-of-Day Signals for MBRX ...

       Recent Intraday Alerts

    Alert Time
    Non-ADX 1,2,3,4 Bearish Retracement Entry 32 minutes ago
    Fell Below Previous Day's Low 32 minutes ago
    Down 1% 32 minutes ago
    Possible NR7 3 days ago
    Possible Inside Day 3 days ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    MBRX Chart by TradingView
    Basic chart:

    Profile

    Moleculin Biotech, Inc., a preclinical and clinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company also develops other drugs, including WP1066 Portfolio, a portfolio of small molecules targeting the modulation of transcription factors involved in cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Pharmaceutical Oncology Acute Myeloid Leukemia Chemotherapy Antineoplastic Drugs Blastoma Glioblastoma Stage Pharmaceutical Transcription Transcription Factors Refractory Acute Myeloid Leukemia Transcription Factor Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia

    Is MBRX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 9 Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
    May 8 Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast
    May 7 Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
    May 2 Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024
    Apr 25 Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
    Apr 18 Moleculin's acute myeloid leukemia treatment gets EMA's orphan drug designation
    Apr 18 European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
    Mar 28 Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
    Mar 27 Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
    Mar 27 Moleculin gets U.S. patent issue notification for annamycin targeting unmet need in AML
    See more MBRX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 15.75
    52 Week Low 4.28
    Average Volume 47,414
    200-Day Moving Average 7.63
    50-Day Moving Average 5.57
    20-Day Moving Average 4.82
    10-Day Moving Average 4.89
    Average True Range 0.44
    RSI (14) 53.05
    ADX 24.39
    +DI 20.51
    -DI 11.92
    Chandelier Exit (Long, 3 ATRs) 4.14
    Chandelier Exit (Short, 3 ATRs) 5.61
    Upper Bollinger Bands 5.35
    Lower Bollinger Band 4.29
    Percent B (%b) 0.75
    BandWidth 22.01
    MACD Line -0.13
    MACD Signal Line -0.22
    MACD Histogram 0.094
    Fundamentals Value
    Market Cap 169.74 Million
    Num Shares 33.4 Million
    EPS -0.89
    Price-to-Earnings (P/E) Ratio -5.71
    Price-to-Sales 0.00
    Price-to-Book 0.48
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 5.26
    Resistance 3 (R3) 5.26 5.20 5.23
    Resistance 2 (R2) 5.20 5.15 5.20 5.22
    Resistance 1 (R1) 5.14 5.13 5.11 5.14 5.21
    Pivot Point 5.08 5.08 5.07 5.08 5.08
    Support 1 (S1) 5.02 5.03 4.99 5.02 4.95
    Support 2 (S2) 4.96 5.01 4.96 4.94
    Support 3 (S3) 4.90 4.96 4.93
    Support 4 (S4) 4.90